Remove Big Data Remove Clinical Research Remove Gene Remove Life Science
article thumbnail

Technology Trends and Collaborations are Ushering in a New Era of ‘Pharmaceutical Intelligence’

ACRP blog

AI is increasingly important in drug discovery and development as well as clinical trials, operations, pharmacovigilance, and many other areas.” This has led to the emergence of a new ‘pharmaceutical intelligence’ that has allowed the industry to move away from traditional, slow-moving, and costly processes,” Lyons writes. “AI

article thumbnail

Drug discovery in 2023: Five key predictions

Drug Discovery World

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. There will be greater emphasis on diversity in clinical trials. In summary, 2023 could be a very exciting year for life sciences.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genmab’s Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics

XTalks

As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

article thumbnail

Medical Informatics and Rare Disease: a bridge between two worlds

pharmaphorum

A very important question was raised by the webinar attendee of the diversity and inclusion of patients in clinical research, and Dr Hackett commented: “A lot of the work has been done in our Paediatric & Rare Disease network, as well as our Cell and Gene Therapy network, we are tackling the issue of diversity in data.

Genome 106